In 2021 "Grindeks" have 10 offices abroad — Lithuania, Estonia, Belarus, Ukraine, Azerbaijan, Georgia, Uzbekistan, Moldova, Kazakhstan, Kyrgyzstan.

[1] In 2009, under the auspices of the Institute of Organic Synthesis of Latvia, independent researchers discovered a new cardioprotective substance GX-EG, which turned out to be 40 times more active than mildronate produced and exported by "Grindeks".

[1] Grindeks manufactures over 60 final dosage form (FDF) pharmaceutical products and exports these to over 90 countries worldwide.

Additionally, to the annual business objectives, Grindeks has set a target to improve the company's activity in the corporate social responsibility area.

[2] The company has defined, that three key priorities of corporate social responsibility are: In 2020 the Grindeks Group achieved historically the sharpest increase in turnover and profit.

Grindeks Group's record-high profit and turnover have been achieved due to a significant increase in demand for the cardiovascular, central nervous system, and hospital segment medicines produced by the Group, as well as the hospital segment offered by JSC Grindeks subsidiary company JSC Kalceks.